07:00 , Oct 26, 2009 |  BC Week In Review  |  Financial News

GlycoMimetics completes venture financing

GlycoMimetics Inc. , Gaithersburg, Md.   Business: Inflammation, Infectious   Date completed: 10/21/09   Type: Venture financing   Raised: $38 million   Investors: New Enterprise Associates; Genzyme Ventures; Anthem Capital; Alliance Technology Ventures  ...
00:45 , Oct 22, 2009 |  BC Extra  |  Financial News

GlycoMimetics raises $38 million

GlycoMimetics Inc. (Gaithersburg, Md.) raised $38 million in a series C round led by New Enterprise Associates. Genzyme Ventures, a new investor, and existing investors Novartis Venture Funds; Anthem Capital; and Alliance Technology Ventures also...
07:00 , Jul 3, 2006 |  BC Week In Review  |  Company News

GlycoMimetics board of directors update

GlycoMimetics Inc. , Gaithersburg, Md.   Business: Inflammation, Infectious   Appointed: Bill Gust, a managing general partner at Anthem Capital  ...
23:48 , Jun 23, 2006 |  BC Extra  |  Financial News

GlycoMimetics raises $15.4 million

Inflammation and infectious company GlycoMimetics (Gaithersburg, Md.) raised $15.4 million in a series B round led by New Enterprise Associates. Existing investors Alliance Technology Ventures; Anthem Capital; Novartis Venture Fund; PTV; and the Maryland Department...
01:28 , Jul 15, 2005 |  BC Extra  |  Financial News

Immune Control raises $11.3 million

Immune Control (West Conshohocken, Penn.) raised $11.3 million in a series A round through BioAdvance Ventures, an early stage venture fund managed by Quaker BioVentures; Domain Associates; NewSpring Capital; and Anthem Capital. Immune Control expects...
07:00 , Apr 5, 2004 |  BioCentury  |  Finance

Ebb & Flow

Private investors continued their love affair with the life sciences, as Alta Partners raised $475 million for two funds last week, and - in a slight change of direction - all of the money will...
08:00 , Apr 1, 2004 |  BC Extra  |  Financial News

Nucleonics raises $40.9 million

RNAi company Nucleonics (Malvern, Penn.) raised $40.9 million in a series B round led by New Enterprise Associates. Other investors included HealthCap; Burrill & Co.; Anthem Capital; POSCO BioVentures; and S.R. One. Nucleonics said it...
08:00 , Mar 29, 2004 |  BioCentury  |  Strategy

All that Jazz . . .

All that Jazz . . . Company Raised Date Focus Investors Jazz $250.0 3/24/04 Neurology, cancer, endocrine Kohlberg Kravis Roberts; Prospect Venture Partners; Versant Ventures; Beecken Petty O'Keefe; Golden Gate Capital; Thoma Cressey Equity Partners;...
08:00 , Mar 15, 2004 |  BioCentury  |  Finance

Ebb & Flow

While VCs continue to pour money into no research-development only companies, drug reprofilers and other fast track business models, at least one NRDO got some push-back from the public markets. After competing its road show...
08:00 , Mar 11, 2004 |  BC Extra  |  Financial News

BioRexis raises $30M

Protein engineering company BioRexis (King of Prussia, Penn.) raised $30 million in a series B round co-led by Prism Venture Partners and Quaker BioVentures. Other investors included Johnson & Johnson Development; Gund Investment; Anthem Capital;...